H. Le Caer

2.2k citations

49 papers · 831 · h-index 13

Impact in

Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Oncology top 10%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies

Papers in

Pulmonary and Respiratory Medicine 21
- Lung Cancer Treatments and Mutations 16
- Lung Cancer Diagnosis and Treatment 7
Oncology 16
- Cancer Diagnosis and Treatment 6
- Lung Cancer Research Studies 5
- Colorectal Cancer Treatments and Studies 5

Co-authors: C. Chouaïd (27 shared papers)A. Vergnenègre (27 shared papers)H. Bérard (15 shared papers)I. Monnet (14 shared papers)H. Léna (6 shared papers)J. Le Treut (5 shared papers)P. Fournel (13 shared papers)G. Robinet (9 shared papers)
Journals: Journal of Clinical Oncology (11 papers)Lung Cancer (6 papers)Annals of Oncology (6 papers)Journal of Thoracic Oncology (5 papers)Clinical Lung Cancer (2 papers)
Partner nations: France Monaco United States

In The Last Decade

H. Le Caer

47 papers receiving 815 citations

Peers

Countries citing papers authored by H. Le Caer

Since Specialization

Citations

This map shows the geographic impact of H. Le Caer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Le Caer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Le Caer more than expected).

Fields of papers citing papers by H. Le Caer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Le Caer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Le Caer. The network helps show where H. Le Caer may publish in the future.

Co-authors

The 25 scholars most cited alongside H. Le Caer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with H. Le Caer Line = papers co-authored together H. Le Caer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·M. Pérol, C. Chouaïd, David Pérol, Fabrice Barlési, Radj Gervais, Virginie Westeel, Jacky Créquit, H. Léna, A. Vergnenègre, Gérard Zalcman, I. Monnet, H. Le Caer, P. Fournel, L. Falchero, M. Poudenx, F. Vaylet, Céline Ségura‐Ferlay, Mojgan Devouassoux‐Shisheboran, Miquel Tarón, B. Milleron	2012	166
2	Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01) Lung Cancer ·C. Chouaïd, C. Dujon, Pascal Dô, Isabelle Monnet, Anne Madroszyk, H. Le Caer, J.B. Auliac, H. Bérard, P. Thomas, H. Léna, G. Robinet, Nathalie Baize, Acya Bizieux‐Thaminy, G. Fraboulet, Chrystèle Locher, J. Le Treut, S. Hominal, A. Vergnenègre	2014	134
3	Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study Annals of Oncology ·J. Le Treut, M. C. Sault, H. Léna, P.-J. Souquet, A. Vergnenègre, H. Le Caer, H. Bérard, S. Boffa, I. Monnet, Diane Damotte, C. Chouaïd	2013	116
4	Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601) Journal of Thoracic Oncology ·C. Decroisette, I. Monnet, H. Bérard, Gilles Quéré, H. Le Caer, Suzanna Bota, Clarisse Audigier-Valette, L. Gérinière, Jean-Marc Vernejoux, C. Chouaïd	2011	99
5	Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer Lung Cancer ·P. Thomas, G. Robinet, S. Gouva, P. Fournel, H. Léna, H. Le Caer, M. Pérol, H. Bérard, P. Bombaron, A. Vergnenègre, J P Kleisbauer	2005	19
6	Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study Lung Cancer ·J.B. Auliac, C. Chouaïd, L. Greiller, I. Monnet, H. Le Caer, L. Falchero, R. Corre, R. Descourt, Suzanna Bota, H. Bérard, Roland Schött, A. Bizieux, P. Fournel, Anaïs Labrunie, Benôıt Marin, A. Vergnenègre	2014	18
7	Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study Journal of Thoracic Oncology ·R. Descourt, A. Vergnenègre, Fabrice Barlési, H. Léna, P. Fournel, L. Falchero, H. Bérard, J. Hureaux, H. Le Caer, Jean Michel Chavaillon, L. Gérinière, I. Monnet, Stéphane Chouabe, G. Robinet	2010	18
8	Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin–vinorelbine with a cisplatin–vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study Annals of Oncology ·M. Pérol, H. Léna, P. Thomas, G. Robinet, P. Fournel, E Coste, C. Belleguic, H. Le Caer, F Blanchon, A. Vergnenègre, J.‐M. Vernejoux, M P Schuller-Lebeau, Erica Pham	2002	16
9	Induction (ICT) or consolidation chemotherapy (CT) with cisplatin (C) and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatin and vinorelbine (V) for unresectable non-small cell lung cancer (NSCLC) patients (pts): Randomized phase II trial GFPC-GLOT-IFCT 02–01 Journal of Clinical Oncology ·P. Fournel, A. Vergnenègre, G. Robinet, H. Léna, R. Gervais, H. Le Caer, P.-J. Souquet, Jean Michel Chavaillon, C. Chouaïd, Isabelle Martel‐Lafay	2006	15
10	Experience of multidisciplinary assessment of elderly patients with cancer in a French general hospital during 1year: A new model care study Journal of Geriatric Oncology ·V. Bouzereau, F. Le Caër, Emmanuel Guardiola, C Scavennec, J.R. Barrière, L. Chaix, H. Le Caer	2013	15
11	Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group Journal of Thoracic Disease ·H. Le Caer, Isabelle Borget, R. Corre, Chrystèle Locher, Christine Raynaud, C. Decroisette, H. Bérard, Clarisse Audigier-Valette, C. Dujon, J.B. Auliac, Jacquy Crequit, I. Monnet, A. Vergnenègre, C. Chouaïd	2017	13
12	Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–Small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 Study (GFPC 0505) Clinical Lung Cancer ·C. Chouaïd, H. Le Caer, R. Corre, Jacquy Crequit, C. Locher, L. Falchero, C. Dujon, H. Bérard, I. Monnet, A. Vergnenègre	2012	12
13	Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer Lung Cancer ·A. Vergnenègre, Casey L. Daniel, H. Léna, P. Fournel, J P Kleisbauer, H. Le Caer, J. Letreut, D. Paillotin, M. Pérol, Eric Bouchaert, Pierre‐Marie Preux, G. Robinet	2004	12
14	Treatment of inoperable elderly head and neck cancer patients Current Opinion in Oncology ·J. Guigay, H. Le Caer, Cécile Ortholan, Anne Aupérin, Cécile Michel, C. Mertens	2019	11
15	Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials Annals of Oncology ·J. Guigay, A. Aupérin, C. Mertens, Caroline Even, Lionnel Geoffrois, Didier Cupissol, Frédéric Rolland, Clément Sire, Jérôme Fayette, Frédéric Peyrade, Emmanuel Blot, P. Debourdeau, Laurence Bozec, Olivier Capitain, Y. Pointreau, Caroline Brard, Cécile Michel, Dominique Schwob, Cécile Ortholan, H. Le Caer	2019	11
16	Assessment of palliative care for advanced non-small-cell lung cancer in France: A prospective observational multicenter study (GFPC 0804 study) Lung Cancer ·A. Vergnenègre, S. Hominal, Achille Tchalla, H. Bérard, Isabelle Monnet, G. Fraboulet, Nathalie Baize, Clarisse Audigier-Valette, G. Robinet, (unknown), H. Le Caer, P. Thomas, L. Gérinière, Bénédicte Mastroïanni, C. Chouaïd	2013	10
17	The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit Annals of Oncology ·C. Mertens, H. Le Caer, Cécile Ortholan, Emmanuel Blot, Caroline Even, Hubert Rousselot, Frédéric Peyrade, Clément Sire, Didier Cupissol, Y. Pointreau, P. Debourdeau, Frédéric Rolland, Jérôme Fayette, Olivier Capitain, X.S. Sun, M. Debbah, Dominique Schwob, Rabia Boulahssass, A. Aupérin, J. Guigay	2017	10
18	Second-Line Oral Chemotherapy (Lomustine, Cyclophosphamide, Etoposide) Versus Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed Small Cell Lung Cancer: A Randomized Phase II Study of GFPC 0501 Clinical Lung Cancer ·Radj Gervais, H. Le Caer, I. Monnet, L. Falchero, Nathalie Baize, G Olivero, P. Thomas, H. Bérard, J.B. Auliac, C. Chouaïd	2014	10
19	Elderly Head and Neck Cancer (ELAN) study: Personalized treatment according to geriatric assessment in patients age 70 or older: First prospective trials in patients with squamous cell cancer of the head and neck (SCCHN) unsuitable for surgery. Journal of Clinical Oncology ·J. Guigay, H. Le Caer, C. Mertens, Cécile Ortholan, Emmanuel Blot, Yungan Tao, Frédéric Peyrade, Y. Pointreau, Pierre Guillet, Cédrik Lafond, Karen Bénézery, S. Renard-Oldrini, Julia Khéde Dourado Villa, Georges Garnier, M. Alfonsi, Naima Lezghed, Nadejda Vintonenko, Dominique Schwob, Perrine Capolino, Anne Aupérin, (unknown)	2014	10
20	A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective Interactive Cardiovascular and Thoracic Surgery ·Fabrice Barlési, C. Chouaïd, Jacky Créquit, H. Le Caer, Jean-Louis Pujol, Julien Legodec, A. Vergnenègre, J. Le Treut, Élizabeth Fabre-Guillevin, Anderson Loundou, Pascal Auquier, Marie-Claude Siméoni, P. Thomas	2015	9

About H. Le Caer

H. Le Caer is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Otorhinolaryngology, Geriatrics and Gerontology and Surgery, having authored 49 papers that have together received 831 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (16 papers), Head and Neck Cancer Studies (10 papers), Frailty in Older Adults (9 papers), Lung Cancer Diagnosis and Treatment (7 papers), Cancer Diagnosis and Treatment (6 papers), Lung Cancer Research Studies (5 papers), Colorectal Cancer Treatments and Studies (5 papers) and Nutrition and Health in Aging (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (444 citations), Oncology (352 citations), Otorhinolaryngology (49 citations), Geriatrics and Gerontology (35 citations) and Cancer Research (81 citations). H. Le Caer has collaborated with scholars based in France, Monaco and United States. Frequent co-authors include C. Chouaïd, A. Vergnenègre, H. Bérard, I. Monnet, H. Léna, J. Le Treut, P. Fournel, G. Robinet, L. Falchero and M. Pérol. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, Annals of Oncology, Journal of Thoracic Oncology and Clinical Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

H. Le Caer

Impact in

Papers in i

In The Last Decade

H. Le Caer

Peers

Countries citing papers authored by H. Le Caer

Fields of papers citing papers by H. Le Caer

All Works

About H. Le Caer

Explore authors with similar magnitude of impact

Papers in